@benwteh Profile picture

Ben Teh

@benwteh

ID physician & clinician researcher @NCICancer @PeterMacCC. #infection #immuneprofiling #myeloma #vaccination

Joined April 2017
Similar User
Michelle Yong photo

@michyong2

NCIC photo

@NCICancer

ASIDANZ photo

@ASIDANZ

Joshua Davis photo

@Josh_S_Davis

Abby Douglas photo

@AbbyPDouglas

NCAS_Australia photo

@NCAS_Aus

Tori Hall photo

@victoriahall26

Adam Stewart photo

@adm_stewart

Dr David Griffin 🦠🧫💉 photo

@drdavidwjg

Brendan McMullan photo

@brendanmcID

Jason Trubiano 🆔 photo

@TrubianoJason

transplantid.net photo

@TransplantIDNet

Orla Morrissey photo

@OrlaMorris61218

Takahiro Matsuo (Taka), MD photo

@TakaMatsuo_ID

Abhay Dhand photo

@DhandAbhay

Ben Teh Reposted

Poster presentations in session… presenting influenza-specific B & T cell analyses in pts w/ haematological malignancy - T cell responses preserved & less dependent on underlying disease and treatment regimen received. @NCICancer @kedzierskalab @id_austin @benwteh @options2024

victoriahall26's tweet image. Poster presentations in session… presenting influenza-specific B & T cell analyses in pts w/ haematological malignancy - T cell responses preserved & less dependent on underlying disease and treatment regimen received. @NCICancer @kedzierskalab @id_austin @benwteh @options2024

Delighted to be part of @NCICancer @monicaslavin CRE to reduce the burden of infection in patients on new gen therapies.

Congratulations to the 20 new NHMRC’s Centres of Research Excellence that will share in an investment of $60 million announced today. Read our media release on our News Centre: ow.ly/NeRY50T0Nsx

nhmrc's tweet image. Congratulations to the 20 new NHMRC’s Centres of Research Excellence that will share in an investment of $60 million announced today. 

Read our media release on our News Centre: <a style="text-decoration: none;" rel="nofollow" target="_blank" href="https://t.co/Za779vgxbn">ow.ly/NeRY50T0Nsx</a>


Ben Teh Reposted

Congratulations to the 20 new NHMRC’s Centres of Research Excellence that will share in an investment of $60 million announced today. Read our media release on our News Centre: ow.ly/NeRY50T0Nsx

nhmrc's tweet image. Congratulations to the 20 new NHMRC’s Centres of Research Excellence that will share in an investment of $60 million announced today. 

Read our media release on our News Centre: <a style="text-decoration: none;" rel="nofollow" target="_blank" href="https://t.co/Za779vgxbn">ow.ly/NeRY50T0Nsx</a>

Ben Teh Reposted

Peter Mac has been awarded 3 significant @nhmrc grants totalling $9m to drive forward innovative approaches in #cancer treatment, lymphatic health and antimicrobial stewardship, led by @BenjaminHogan13, @monicaslavin and Prof Karin Thursky. More 👇 petermac.org/about-us/news-…


Wonderful work by @GemmaKReynolds queen of systematic rev and meta-analysis!

Infections in patients with lymphoma treated with bispecific antibodies: a systematic review and meta-analysis ow.ly/nLIA50Sy9Cp #clinicaltrialsandobservations #lymphoidneoplasia



A global call to encourage the use of standard reporting of infection AEs so we can advance research in the field. It was also mentioned at #ESCMIDGlobal2024

Consensus position statement on advancing the standardised reporting of infection events in immunocompromised patients [Sep 6, 2023] @benwteh et al. @TheLancetInfDis doi.org/10.1016/S1473-… #IDonc #leusm #lymsm #mmsm #mpnsm #caxtx

mtmdphd's tweet image. Consensus position statement on advancing the standardised reporting of infection events in immunocompromised patients [Sep 6, 2023] @benwteh et al. @TheLancetInfDis <a style="text-decoration: none;" rel="nofollow" target="_blank" href="https://t.co/G0SZb7Pyc4">doi.org/10.1016/S1473-…</a> #IDonc #leusm #lymsm #mmsm #mpnsm #caxtx


Ben Teh Reposted

Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis [Oct 10, 2023] @GemmaKReynolds et al. @benwteh @BloodAdvances ashpublications.org/bloodadvances/… #IDonc #mmsm #caxtx

mtmdphd's tweet image. Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis [Oct 10, 2023] @GemmaKReynolds et al. @benwteh @BloodAdvances <a style="text-decoration: none;" rel="nofollow" target="_blank" href="https://t.co/k1uPIqIOD6">ashpublications.org/bloodadvances/…</a> #IDonc #mmsm #caxtx

Ben Teh Reposted

#ECCMID2024 Hot topic 🔥 of developing AI tools for infection detection. Anna Khanina @NCICancer @NCAS_Aus explaining the laborious manual process and aiming for AI detection. Check out this cool dashboard for fungal infections IFIS!!! Coming soon

michyong2's tweet image. #ECCMID2024 Hot topic 🔥 of developing AI tools for infection detection. Anna Khanina @NCICancer @NCAS_Aus explaining the laborious manual process and aiming for AI detection. Check out this cool dashboard for fungal infections IFIS!!! Coming soon
michyong2's tweet image. #ECCMID2024 Hot topic 🔥 of developing AI tools for infection detection. Anna Khanina @NCICancer @NCAS_Aus explaining the laborious manual process and aiming for AI detection. Check out this cool dashboard for fungal infections IFIS!!! Coming soon
michyong2's tweet image. #ECCMID2024 Hot topic 🔥 of developing AI tools for infection detection. Anna Khanina @NCICancer @NCAS_Aus explaining the laborious manual process and aiming for AI detection. Check out this cool dashboard for fungal infections IFIS!!! Coming soon
michyong2's tweet image. #ECCMID2024 Hot topic 🔥 of developing AI tools for infection detection. Anna Khanina @NCICancer @NCAS_Aus explaining the laborious manual process and aiming for AI detection. Check out this cool dashboard for fungal infections IFIS!!! Coming soon

Ben Teh Reposted

#ECCMID2024 Results from RCT of SD vs AD flu vaccine as a strategy for high-risk HM group by @victoriahall26 @NCICancer @benwteh showing no difference in primary outcome seroconversion but highlighting the CLL NHL groups as having poor responses in general. How to improve this?

michyong2's tweet image. #ECCMID2024 Results from RCT of SD vs AD flu vaccine as a strategy for high-risk HM group by @victoriahall26 @NCICancer @benwteh showing no difference in primary outcome seroconversion but highlighting the CLL NHL groups as having poor responses in general. How to improve this?
michyong2's tweet image. #ECCMID2024 Results from RCT of SD vs AD flu vaccine as a strategy for high-risk HM group by @victoriahall26 @NCICancer @benwteh showing no difference in primary outcome seroconversion but highlighting the CLL NHL groups as having poor responses in general. How to improve this?
michyong2's tweet image. #ECCMID2024 Results from RCT of SD vs AD flu vaccine as a strategy for high-risk HM group by @victoriahall26 @NCICancer @benwteh showing no difference in primary outcome seroconversion but highlighting the CLL NHL groups as having poor responses in general. How to improve this?
michyong2's tweet image. #ECCMID2024 Results from RCT of SD vs AD flu vaccine as a strategy for high-risk HM group by @victoriahall26 @NCICancer @benwteh showing no difference in primary outcome seroconversion but highlighting the CLL NHL groups as having poor responses in general. How to improve this?

Hot off the press - late breaking data from @victoriahall26 @NCICancer demonstrating similiar immunogenicity from two different vax strategies and no incremental benefit of second dose. #ESCMIDGlobal2024 #TxID

benwteh's tweet image. Hot off the press - late breaking data from @victoriahall26 @NCICancer demonstrating similiar immunogenicity from two different vax strategies and no incremental benefit of second dose. #ESCMIDGlobal2024 #TxID
benwteh's tweet image. Hot off the press - late breaking data from @victoriahall26 @NCICancer demonstrating similiar immunogenicity from two different vax strategies and no incremental benefit of second dose. #ESCMIDGlobal2024 #TxID
benwteh's tweet image. Hot off the press - late breaking data from @victoriahall26 @NCICancer demonstrating similiar immunogenicity from two different vax strategies and no incremental benefit of second dose. #ESCMIDGlobal2024 #TxID

An amazing nation wide randomised trial of a simple reminder transforming vaccination uptake, even in immune compromised. Elegant solution. #ESCMIDGlobal2024 #TxID

benwteh's tweet image. An amazing nation wide randomised trial of a simple reminder transforming vaccination uptake, even in immune compromised. Elegant solution. #ESCMIDGlobal2024 #TxID
benwteh's tweet image. An amazing nation wide randomised trial of a simple reminder transforming vaccination uptake, even in immune compromised. Elegant solution. #ESCMIDGlobal2024 #TxID

Thanks for coming to our session. @NATBASH15 and i had fun with our talks. Hope it was useful! #ESCMIDGlobal2024 #TxID

benwteh's tweet image. Thanks for coming to our session. @NATBASH15 and i had fun with our talks. Hope it was useful! #ESCMIDGlobal2024 #TxID

Superb and hard work from @victoriahall26 PhD extraordinaire. Another impactful collab with @kedzierskalab . Will guide future long acting MoAb Prep practice. #TxID

Evolution of humoral and cellular immunity post breakthrough COVID-19 in vaccinated patients with hematologic malignancy receiving tixagevimab-cilgavimab ✅ Just Accepted 🔓 Open Access 🔗 bit.ly/46WUq7J @victoriahall26 @benwteh @monicaslavin @kedzierskalab @ncicancer

OFIDJournal's tweet image. Evolution of humoral and cellular immunity post breakthrough COVID-19 in vaccinated patients with hematologic malignancy receiving tixagevimab-cilgavimab

✅ Just Accepted
🔓 Open Access
🔗 <a style="text-decoration: none;" rel="nofollow" target="_blank" href="https://t.co/AbwxNA1gup">bit.ly/46WUq7J</a>

@victoriahall26 @benwteh @monicaslavin @kedzierskalab @ncicancer


Ben Teh Reposted

In light of updated MajesTEC-1 data at #IMS23 this week showing infection-related mortality of 12.7%(!), it is timely to see the nicely-formatted version of our systematic review just out in @BloodAdvances @GemmaKReynolds #mmsm @ManniMD1

Eddie_Cliff's tweet image. In light of updated MajesTEC-1 data at #IMS23 this week showing infection-related mortality of 12.7%(!), it is timely to see the nicely-formatted version of our systematic review just out in @BloodAdvances 

@GemmaKReynolds #mmsm @ManniMD1
Eddie_Cliff's tweet image. In light of updated MajesTEC-1 data at #IMS23 this week showing infection-related mortality of 12.7%(!), it is timely to see the nicely-formatted version of our systematic review just out in @BloodAdvances 

@GemmaKReynolds #mmsm @ManniMD1
Eddie_Cliff's tweet image. In light of updated MajesTEC-1 data at #IMS23 this week showing infection-related mortality of 12.7%(!), it is timely to see the nicely-formatted version of our systematic review just out in @BloodAdvances 

@GemmaKReynolds #mmsm @ManniMD1
Eddie_Cliff's tweet image. In light of updated MajesTEC-1 data at #IMS23 this week showing infection-related mortality of 12.7%(!), it is timely to see the nicely-formatted version of our systematic review just out in @BloodAdvances 

@GemmaKReynolds #mmsm @ManniMD1

Ben Teh Reposted

sciencedirect.com/science/articl… 🔥 New article from @GemmaKReynolds @BeaCereus @monicaslavin @benwteh Systematic review and meta-analysis of infections in HM patients treated with CAR-T. Bacterial more common than viral or fungal post CAR-T, 17% developed serious infection.


Valuable contribution and leadership from the ASID ICH SIG #TxiD

Congratulations @benwteh - we posted this on the @ASIDANZ website. #showcase #membership asid.net.au/blog/developme…



Loading...

Something went wrong.


Something went wrong.